Cognitive effects of chemotherapy
The Other oncological emergencies page has been updated with a short mention of the cognitive effects of chemotherapy.
Dunn RJ
The Other oncological emergencies page has been updated with a short mention of the cognitive effects of chemotherapy.
The Other anti-coagulants page has been reorganised to prioritise content relevant to the most common DOACs – as well as making a few edits along the way.
A table summarising the treatment of DVT in various situations has been added to the Management of DVT page.
Links to the NOAC, heparin and warfarin pages have been added to the Management of PE and Management of DVT pages.
The section on HUS has been revised, particularly with an extended list of potential triggers, on the Thrombotic microangiopathies page.
The section on HUS that was on the Paediatric gastroenteritis page has been moved to the section on HUS on the Thrombotic micorangiopathies page.
The Febrile neutropenia page has been updated with a segment on the MASCC febrile neutropenia risk index.
The Other anticoagulants page has been updated including apixaban dosing information for stroke and DVT prophylaxis. Rivaroxaban dosing has also been clarified.
The Thrombotic microangiopathies page has been updated with information about the role of monoclonal antibodies as therapy.
The Disorders of clotting page has been updated and some additional information about acquired factor deficiencies has been added.
AKI has been added as a complication to the Bone marrow transplantation page. Hingorani, S. Renal Complications of Hematopoietic-Cell Transplantation. New England Journal of Medicine 2016;374(23):2256-67.
Ethnicity has been added as a risk factor for VTE to the Deep venous thrombosis page. Liao, S, McAnulty, K, Lim, C, et al. Ethnicity as an independent predictive factor for the results of CT pulmonary angiography and ultrasonography of the lower limbs. Internal Medicine Journal 2016:n/a-n/a.
The Deep venous thrombosis page has been updated with a segment on May-Thurner syndrome, estimated to cause 2-5% of DVTs. Lee, AI, Ochoa Chaar, CI. The Hidden Lesion. N Engl J Med 2016;374(22):2160-65.
The Management of DVT page has been updated with the rates of complications revised downwards from those previously quoted. Horner, D, Hogg, K, Body, R. Should we be looking for and treating isolated calf vein thrombosis? Emergency Medicine Journal 2016;33(6):431-37.
The Management of DVT page has been updated with information about the use of oestrogens in anticoagulated patients with VTE.
A new segment on Scurvy has been added to the Anaemia page. Even though scurvy also has skin, bone and CNS features the reason it has been put there is that anaemia is the most consistent finding in scurvy.
The Reversal of anti-coagulation page has been updated with a segment on idarucizumab and its role in reversing dabigatran toxicity.
A small segment on the usually benign course of rivaroxaban or apixaban overdose as a single ingestion in otherwise healthy people has been added to the Reversal of anti-coagulation page.
The Thrombotic microangiopathies page has been updated. particularly in relation to the segment on TTP.
Additional information about the risk factors for propagation, and treatment of, isolated below knee DVT has been added to the Management of DVT page.